AUSTIN, Texas–(BUSINESS WIRE)–Maxwell Biosciences (“Maxwell”), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced the appointments of three senior executives: Tony Verco, MD, MBA, as Chief Medical Officer; Beth Burnside, PhD, as Senior Vice President of Research and Development (R&D) Strategy; and Donald Treacy, Jr., PhD, as Senior Vice President, Development Operations. The appointments further strengthen Maxwell’s management team, bringing industry-leading leadership to support the company’s clinical R&D strategy and operations.
“As Maxwell looks to accelerate the progress of its CLAROMER™ drug platform, we are pleased to welcome Tony, Beth, and Don,” said Maxwell Biosciences CEO and Co-Founder, Joshua McClure. “I am confident that the appointments of these industry veterans – who bring extensive depth and breadth of expertise – will further strengthen our world-class team and position us to more rapidly realize the benefits of our platform, offering a new approach to safely and effectively inactivate viruses, bacteria and fungi to benefit patients across a variety of infections.”
Tony Verco, MD, MBA has over 25 years of international biotech and pharmaceutical experience, with a specific focus on early-stage drug development, operational oversight, and pharmacovigilance of clinical trial programs. He most recently was the owner of Shelton Clinical Research Consultants, LLC, and previously held leadership roles at Medwell Capital Corp. (formerly BioMS Medical Corp.), Endpoint Research and AstraZeneca, UK. He also held Unit Physician and Principal Investigator roles at AstraZeneca, UK, and Leicester Clinical Research Center. He holds a Bachelor of Medicine, Bachelor of Surgery (MD) from the University of the Witwatersrand in South Africa, a Masters in Business Administration (MBA) from New York Institute of Technology in the U.S., and a Diploma in Anaesthetics (DA) from the Royal College of Medicine in South Africa.
Over the past 30 years, Beth Burnside, PhD, has led teams across drug development and delivery, enhanced drug absorption, regulatory affairs, quality and corporate compliance, and intellectual property strategy. She has served as lead inventor or co-inventor on more than 34 issued U.S. patents and numerous related international patents, including developing several pharmaceutical products such as Adderall XR®, Intuniv®, and MOXATAG®. Prior to joining Maxwell, she held executive roles with Lowery Creek Consulting, LLC, QRxPharma, MiddleBrook Pharmaceuticals, Inc. (formerly Advancis Corporation), and Shire Pharmaceuticals. She holds a PhD in Physical Organic Chemistry and an MS in Organic Chemistry, both from Drexel University, and a BS in Chemistry and Mathematics from Muhlenberg College.
Donald Treacy, Jr., PhD, brings 30 years of experience across the biotech and pharmaceutical industry, with diverse expertise across research, product development and manufacturing, and regulatory affairs. He most recently was the CEO of Magothy Consulting Group, LLC, and previously held the role of Senior Vice President of Development and Manufacturing Operations at MiddleBrook Pharmaceuticals, Inc. (formerly Advancis Corporation), and Senior Director of Analytical Sciences at Shire Pharmaceuticals. He is the named inventor on over 30 issued U.S. and international patents in novel drug delivery, solid dosage form development and formulation performance, and has authored numerous research publications and presentations on accelerator mass spectrometry, high performance liquid chromatography, and novel drug delivery systems. He holds a PhD in Analytical and Nuclear Chemistry from the University of Maryland, and a BA in Chemistry from Roanoke College.
Founded in 2016, Maxwell Biosciences is a preclinical drug platform company which develops biomimetic therapeutics – synthetic compounds that mimic and improve upon biomolecules. Inspired by nature, these low-molecular weight compounds are created by Maxwell’s exclusive first-in-class, CLAROMER™ brand drug platform and have been shown to be effective in destroying viruses, bacteria, fungi and some cancers, while safely avoiding healthy cells. These drug candidates have been shown to be well-tolerated in human tissues in vitro, and in animal studies. The compounds imitate key components of the immune system, humanity’s greatest asset in fighting disease. Maxwell’s technology is protected by granted patents and is led by a world-class team of experienced life science executives. To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com, or follow us on Twitter and LinkedIn.